ReviewDiagnostics (Basel, Switzerland)2017
Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.
Review in Diagnostics (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Misfolded Proteins and Cognitive Decline: Mechanistic Insights into Neurodegenerative Disorders.Neurology international · 2026Review
- 2-Styrylquinolines with Push-Pull Architectures as Sensors for β-Amyloid Aggregation with Theranostic Properties.International journal of molecular sciences · 2025Article
- A Systems Biology Approach to Memory Health: Integrating Network Pharmacology, Gut Microbiota, and Multi-Omics for Health Functional Foods.International journal of molecular sciences · 2025Review
- Review
- Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease.CNS neuroscience & therapeutics · 2023Review
- Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.Brain sciences · 2022Article
- Early Memory Impairment is Accompanied by Changes in GluA1/ p-GluA1 in APP/PS1 Mice.Current Alzheimer research · 2022Article
- Perivascular spaces as a potential biomarker of Alzheimer's disease.Frontiers in neuroscience · 2022Review
- A molecular journey to check the conformational dynamics of tau tubulin kinase 2 mutations associated with Alzheimer's disease.RSC advances · 2021Article
- Body Fluid Biomarkers for Alzheimer's Disease-An Up-To-Date Overview.Biomedicines · 2020Review
- [Young onset dementia].Der Nervenarzt · 2020Review
- Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2020Review
- Article
- Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease.Current neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is the most common cause of dementia. Over the last three decades, research has advanced dramatically and provided a detailed understanding of the molecular events underlying the pathogenesis of Alzheimer's disease. In parallel, assays for the detection of biomarkers that reflect the typical Alzheimer's disease-associated pathology have been developed and validated in myriads of clinical studies. Such biomarkers complement clinical diagnosis and improve diagnostic accuracy. The use of biomarkers will become even more important with the advent of disease-modifying therapies. Such therapies will likely be most beneficial when administered early in the disease course. Here, we summarise the development of the core Alzheimer's disease cerebrospinal fluid biomarkers: amyloid-β and tau. We provide an overview of their role in cellular physiology and Alzheimer's disease pathology, and embed their development as cerebrospinal fluid biomarkers into the historical context of Alzheimer's disease research. Finally, we summarise recommendations for their use in clinical practice, and outline perspectives for novel cerebrospinal fluid candidate biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.